PURPOSE: Submucosal collagen is paramount for colonic anastomotic integrity. Matrix metalloproteinases (MMPs) mediate collagen degradation that increases the risk of wound dehiscence. Although broad-spectrum MMP inhibitors are beneficial for anastomotic strength, they can cause adverse reactions. Knowledge of specific MMPs responsible for the weakening of anastomoses can be used to optimise MMP inhibition therapy. We aimed to quantify transcript and protein levels of multiple MMPs in colonic anastomoses and evaluate the effect of inhibiting the MMPs that displayed the highest expression levels on anastomotic repair. METHODS: Left-sided colonic anastomoses were made in male Sprague-Dawley rats. After 3 days when biomechanical strength is lowest, MMP mRNA and protein levels were measured by quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assays and gelatin zymography. The effects of the MMP-8, MMP-9 and MMP-12 synthetic inhibitor AZD3342 was also studied. RESULTS: MMP-8, MMP-9 and MMP-12 gene and protein expression increased profoundly (p < 0.01), and MMP-13 mRNA and MMP-2 mRNA and protein modestly (p < 0.001) in the anastomoses. MMP-3 mRNA levels were not up-regulated significantly compared with adjacent uninjured colon. Increased anastomotic MMP-12 levels paralleled macrophage infiltration by immunohistochemical analyses. AZD3342 (50 mg/kg) treatment increased the anastomotic breaking strength by 29% (p = 0.015) day 3 compared with vehicle. Improved anastomotic strength was not accompanied with alterations of type I or type III procollagen mRNA but was possibly due to inhibition of the concerted digestive action on the existent submucosal collagens by the targeted MMPs. CONCLUSION: The present findings justify the concept of selective MMP inhibition to enhance anastomotic strength in colon.
PURPOSE: Submucosal collagen is paramount for colonic anastomotic integrity. Matrix metalloproteinases (MMPs) mediate collagen degradation that increases the risk of wound dehiscence. Although broad-spectrum MMP inhibitors are beneficial for anastomotic strength, they can cause adverse reactions. Knowledge of specific MMPs responsible for the weakening of anastomoses can be used to optimise MMP inhibition therapy. We aimed to quantify transcript and protein levels of multiple MMPs in colonic anastomoses and evaluate the effect of inhibiting the MMPs that displayed the highest expression levels on anastomotic repair. METHODS: Left-sided colonic anastomoses were made in male Sprague-Dawley rats. After 3 days when biomechanical strength is lowest, MMP mRNA and protein levels were measured by quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assays and gelatin zymography. The effects of the MMP-8, MMP-9 and MMP-12 synthetic inhibitor AZD3342 was also studied. RESULTS:MMP-8, MMP-9 and MMP-12 gene and protein expression increased profoundly (p < 0.01), and MMP-13 mRNA and MMP-2 mRNA and protein modestly (p < 0.001) in the anastomoses. MMP-3 mRNA levels were not up-regulated significantly compared with adjacent uninjured colon. Increased anastomotic MMP-12 levels paralleled macrophage infiltration by immunohistochemical analyses. AZD3342 (50 mg/kg) treatment increased the anastomotic breaking strength by 29% (p = 0.015) day 3 compared with vehicle. Improved anastomotic strength was not accompanied with alterations of type I or type III procollagen mRNA but was possibly due to inhibition of the concerted digestive action on the existent submucosal collagens by the targeted MMPs. CONCLUSION: The present findings justify the concept of selective MMP inhibition to enhance anastomotic strength in colon.
Authors: Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall Journal: Curr Opin Cell Biol Date: 2009-07-16 Impact factor: 8.382
Authors: A H Drummond; P Beckett; P D Brown; E A Bone; A H Davidson; W A Galloway; A J Gearing; P Huxley; D Laber; M McCourt; M Whittaker; L M Wood; A Wright Journal: Ann N Y Acad Sci Date: 1999-06-30 Impact factor: 5.691
Authors: Gregory A Bannikov; Tatiana V Karelina; Ivan E Collier; Barry L Marmer; Gregory I Goldberg Journal: J Biol Chem Date: 2002-02-11 Impact factor: 5.157
Authors: Peter-Martin Krarup; Mikkel Eld; Lars Nannestad Jorgensen; Mark Berner Hansen; Magnus S Ågren Journal: Int J Colorectal Dis Date: 2017-07-17 Impact factor: 2.571
Authors: Marie Kjaer; Hrefna Kristjánsdóttir; Line Andersen; Anne-Marie Heegaard; Magnus S Ågren; Lars N Jorgensen Journal: Int J Colorectal Dis Date: 2018-05-31 Impact factor: 2.571
Authors: Martin Rehn; Peter-Martin Krarup; Lise H Christensen; Jakob B Seidelin; Magnus S Ågren; Ingvar Syk Journal: Surg Infect (Larchmt) Date: 2015-07-14 Impact factor: 2.150
Authors: Benjamin D Shogan; Natalia Belogortseva; Preston M Luong; Alexander Zaborin; Simon Lax; Cindy Bethel; Marc Ward; Joseph P Muldoon; Mark Singer; Gary An; Konstantin Umanskiy; Vani Konda; Baddr Shakhsheer; James Luo; Robin Klabbers; Lynn E Hancock; Jack Gilbert; Olga Zaborina; John C Alverdy Journal: Sci Transl Med Date: 2015-05-06 Impact factor: 17.956
Authors: Moritz J Strowitzki; Gwendolyn Kimmer; Julian Wehrmann; Alina S Ritter; Praveen Radhakrishnan; Vanessa M Opitz; Christopher Tuffs; Marvin Biller; Julia Kugler; Ulrich Keppler; Jonathan M Harnoss; Johannes Klose; Thomas Schmidt; Alfonso Blanco; Cormac T Taylor; Martin Schneider Journal: JCI Insight Date: 2021-03-30